Second Line Chemotherapy for Advanced Pancreatic Cancer (SLAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01543412|
Recruitment Status : Completed
First Posted : March 5, 2012
Last Update Posted : March 5, 2012
No validated second-line chemotherapy for the treatment of locally advanced/metastatic pancreatic cancer is actually available,after the failure of a gemcitabine(+/- Cisplatin or Oxaliplatin)-based regimen.
Irinotecan seems to be a moderately active drug in the treatment of this disease Recently was reported some interesting results using a potentially non -cross resistant regimen (FOLFIRI) which could be useful even as second-line chemotherapy.
An exploratory study in this setting seem warranted.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Adenocarcinoma||Drug: FOLFIRI||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Folfiri as Second-Line Chemotherapy for Advanced Pancreatic Cancer. A GISCAD Phase II Study|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||June 2011|
|Actual Study Completion Date :||December 2011|
Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
- Overall Response Rate (RECIST Criteria) [ Time Frame: 2 years ]time from randomization date to date of death from any cause
- Safety and tolerability; Safety (CTC criteria - version 3.0) [ Time Frame: 18 months ]Treatment will consist of 4 combination-chemotherapy cycles and in case of stable or responsive disease, other 4 cycles can be administered at investigator's discretion. Therefore will be administered for up to 6 months Each treatment cycle will consist of 2 weeks, unless the start of the subsequent cycle is delayed, in which case the cycle length will be longer than 4 weeks.
- Overall survival (OS) [ Time Frame: time from first cycle to death ]
OS is calculated using the Kaplan-Meyer method The principal objective of the trial is to assess the therapeutic activity of FOLFIRI in patients with exocrine pancreas carcinoma.
The primary activity parameter to be determined is overall response rate.
- Progression Free Survival [ Time Frame: time from first cycle to progression or death ]PFS was calculated using the Kaplan-Meyer method Presence of at least one target lesion measurable by CT scan or MRI in not an irradiated area (and conform with the RECIST criteria)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01543412
|A.O. Treviglio-Caravaggio, P.le Ospedale n1|
|Treviglio, Bergamo, Italy, 24047|
|Azienda Ospedaliera "Di Liegro"|
|Gaeta, Latina, Italy, 04024|
|A.O. Ospedale S.Paolo|
|Milano, MI, Italy, 20100|
|Pesaro, PS, Italy, 61100|
|Sondalo, SO, Italy, 23100|
|Ospedali Riuniti Umberto I - GM Lancisi-G Salesi|
|Ancona, Italy, 60126|
|Ospedali Riuniti, Largo Barozzi, 1|
|Bergamo, Italy, 24128|
|Fondazione Poliambulanza, Via Bissolati 57|
|Brescia, Italy, 25100|
|A.O. Carlo Poma - Via Albertoni, 1|
|Mantova, Italy, 46100|
|Study Chair:||Alberto Zaniboni, MD||Fondazione GISCAD|
|Principal Investigator:||Roberto Labianca, MD||Fondazione GISCAD|